Form 483

Fougera Pharmaceuticals, LLC Form 483, 2012-06-15

FDA issued a Form 483 to Fougera Pharmaceuticals, LLC on 2012-06-15 with 4 public-safe observations.

483· Form 483 issued4 observations

Fougera Pharmaceuticals, LLC · Melville, United States · Issued June 15, 2012

Overview

  • 4 public-safe observations are available for this inspection.
  • 4 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

15 Jun 2012
21 CFR 211.65(a)

Equipment construction - reactive surfaces

Cited by Alice S Tsao

15 Jun 2012
21 CFR 211.110(b)

In-process materials specifications

Cited by Alice S Tsao

15 Jun 2012
21 CFR 211.165(f)

Failing drug products not rejected

Cited by Alice S Tsao

15 Jun 2012
21 CFR 211.166(a)

Written program not followed

Cited by Alice S Tsao

Inspected site

FPFougera Pharmaceuticals, LLCMelville, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.110(b)Cited across public-safe Form 483 observations1x
21 CFR 211.165(f)Cited across public-safe Form 483 observations1x
21 CFR 211.166(a)Cited across public-safe Form 483 observations1x
21 CFR 211.65(a)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 4 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere